Data-Driven Healthcare Real Estate: Didier Choukroun on Building SPHERE Investments

Title: Building a Data-Driven Healthcare Real Estate Empire with Didier ChoukrounGuest: Didier Choukroun, Founder & CEO of SPHERE Healthcare InvestmentsHost: Swati Chaturvedi, CEO of Propel(x)Episode Overview:In this episode, Swati Chaturvedi talks with Didier Choukroun, the visionary behind SPHERE Healthcare Investments, a leading healthcare-focused real estate investment firm. Didier shares his journey from his early career in France and Latin America to establishing SPHERE in the U.S., expanding into Europe, and building a $1.3 billion portfolio across 15 U.S. states and several European countries.Key Discussion Points:Didier’s career journey: From real estate development in France to entrepreneurship in Latin America and the U.S.Founding SPHERE in 2010 with a mission to improve public health through healthcare real estate investment.SPHERE’s unique investment approach:Data-driven strategy: Using proprietary healthcare analytics for smarter decision-making.Vertical integration: Managing every stage of the investment process in-house.Multidisciplinary team: Physicians, public health experts, and data scientists working together to optimize investment outcomes.SPHERE’s portfolio highlights:39 assets across 15 U.S. states, plus France, Spain, Italy, and soon the UK.Average IRR of 23.5% and annual cash yields above 10%.Successful track record of 12 asset dispositions with exceptional returns.The role of SPHERE’s proprietary data platform in mitigating risk and identifying opportunities.The importance of building authentic relationships with healthcare operators.Partnership with Propel(x) to make institutional-grade healthcare real estate opportunities accessible to accredited retail investors.Didier’s insights on risk management, investment strategy, and leveraging data for long-term success in healthcare real estate.Why Listen:This episode is packed with actionable insights for investors, healthcare professionals, and anyone curious about the intersection of real estate, data analytics, and public health. Didier’s story illustrates how strategic vision, data-driven decision-making, and operational expertise can create a resilient, high-performing investment firm.Resources & Links:SPHERE InvestmentsPropel(x)Timestamps:00:00 – Welcome & Introduction00:45 – Overview of SPHERE Healthcare Investments02:57 – SPHERE’s building blocks: data, team, vertical integration04:27 – Portfolio size, assets, and track record12:11 – Didier’s early career and entrepreneurial journey19:40 – Early U.S. investments and lessons learned27:24 – SPHERE’s current data-driven strategy34:07 – Partnership with Propel(x)40:35 – Final thoughts for the audience

Discussion Points(4:12) What does the NSF look for in companies?(6:05) How does the selection process work?(10:05) What are the non-technical elements of the awards program?(19:12) Examples of breakout success in the NSF portfolio(21:14) What distinguishes a novel technology from a promising technology based startup?(24:45) NSF's outreach efforts for diversity and inclusion(29:16) Why should the government finance technology risk?ReferencesNational Science FoundationBayh-Dole Act 1980 (Wikipedia)Ginko BioworksOpus 12Marinus AnalyticsTopicsGrant funding for science startupsStartup investingCommercializationInvesting diligenceEvaluating teamGet to know Propel(x)Propel(x) TwitterPropel(x) LinkedInJoin Propel(x) as an Accredited InvestorAndy Reed

Discussion points(2:43) What is Deep Tech?(6:26) How do you gauge commercial readiness for Deep Tech?(8:51) How do you evaluate the unique risk factors of Deep Tech startups?(13:42) How does alignment and investment strategy create value as a venture investor?(18:35) Bridging the technical founder to successful commercial founder gap.(25:20) What areas of deep tech will be the biggest drivers of innovation and growth in the next investment period?ReferencesTsingyuan VenturesTEEC AngelsTsingyua UniversityZoomGinko BioworksSynthetic biology (Wikipedia)Ambilight smart glassMission BioWeRidePlus.aiApplied VenturesTDK VenturesxMems microspeakersSubtle MedicalTopicsDeep Tech (deeptech) startupsArtificial intelligenceSynthetic biologyGeneticsAutonomous drivingVenture Capital InvestingInvesting StrategyTechnical risk & due diligenceGet to know Propel(x)Propel(x) TwitterPropel(x) LinkedInJoin Propel(x) as an Accredited InvestorAndy Reed

Discussion Points(0:30) What is product-go-to-market fit?(3:00) Why isn't Climate Tech just Cleantech 2.0?(8:00) How do you source good deals efficiently?(17:00) Who else supports Climate Tech?(23:31) What lessons did you learn from your first successful investment that are still relevant today? ReferencesBaruch Future VenturesJason HoltTom BaruchGeltorCyclotron RoadMIT EngineBreakthrough Energy VenturesNew Energy NexusLawrence Berkeley National LabsUS Department of EnergyNational Science Foundation Innovation Corps (ICORPS)M34 CapitalMaxygenFrances H. Arnold Group at CaltechKauffman FoundationTopicsInvestment DiligenceHard TechTough TechCarbon TechDecarbonizationTechnology commercializationCleantechSynthetic BiologyProduct Market FitElectrificationSustainable ProtiensPivotsClimate CatastropheWildfiresClimate ChangeHopeSolar and Wind EnergyGeothermal Get to know Propel(x)Propel(x) TwitterPropel(x) LinkedInJoin Propel(x) as an Accredited InvestorAndy Reed

In this episode we begin to analyze the Internal Risks of a company - Technology, Regulatory and IP risks are covered in this episode. Join us as we define each of the risks, and discuss the key considerations for each. Disclaimer: Propel(x) is a funding platform, not a Broker-Dealer. Securities are offered through Hubble Investments, member FINRA/SIPC and an affiliate of Propel(x). Private investments are highly illiquid and risky and are not suitable for all investors. Past performance is not indicative of future results. You should speak with your financial advisor, accountant, and/or attorney when evaluating private offerings. Neither Propel(x) nor Hubble Investments makes any recommendations or provides advice about investments.

In Episode 4 we had put out a framework for 'How to Evaluate a Startup'. Episodes 6 and 7 discussed 'How to Evaluate the Market' and 'How to Evaluate the Team', respectively. In this episode, we continue the discussion on how to evaluate a startup. Today we discuss how to evaluate competition. Highlights of this episode: - Status quo, or how customers currently solve their problem, is always a competitor (often the main competitor) - Good competitors improve one of three things for their customers: 1) they are lower cost 2) they are higher performance or 3) they are more convenient. - Talking to customers or industry experts is one of the best ways to learn about competition. Disclaimer: Propel(x) is a funding platform, not a Broker-Dealer. Securities are offered through Hubble Investments, member FINRA/SIPC and an affiliate of Propel(x). Private investments are highly illiquid and risky and are not suitable for all investors. Past performance is not indicative of future results. You should speak with your financial advisor, accountant, and/or attorney when evaluating private offerings. Neither Propel(x) nor Hubble Investments makes any recommendations or provides advice about investments.

Join us as Swati discusses the process of investing with Gopi Rangan, an experienced investor in the insurance technology sector. We discuss the explosion of Micro VCs in recent times. Additionally, Gopi shares his process, how he sources companies, how he interacts with them, what characteristics he specifically looks for and he manages his portfolio post investment. As an early stage investor, Gopi seeks to understand how he can help the company grow and thrive. Disclaimer: Propel(x) is a funding platform, not a Broker-Dealer. Securities are offered through Hubble Investments, member FINRA/SIPC and an affiliate of Propel(x). Private investments are highly illiquid and risky and are not suitable for all investors. Past performance is not indicative of future results. You should speak with your financial advisor, accountant, and/or attorney when evaluating private offerings. Neither Propel(x) nor Hubble Investments makes any recommendations or provides advice about investments.

Professional investors cite 'team' as the single most important criterion that influences the investment decision. Yet, there are no precise metrics that guide the evaluation of the team. The assessment is often fuzzy, vague, and based on how the investor 'feels' about the team. This episode presents three tips that early stage investors should keep in mind when evaluating team: 1. Early stage investing is subject to behavioral bias. Be aware of your biases. 2. Separate fact from opinion and focus on the facts when evaluating team. 3. Ask questions to cross check facts. E.g., who is really on the payroll vs. an advisor at large. Disclaimer: Propel(x) is a funding platform, not a Broker-Dealer. Securities are offered through Hubble Investments, member FINRA/SIPC and an affiliate of Propel(x). Private investments are highly illiquid and risky and are not suitable for all investors. Past performance is not indicative of future results. You should speak with your financial advisor, accountant, and/or attorney when evaluating private offerings. Neither Propel(x) nor Hubble Investments makes any recommendations or provides advice about investments.

In Episode 4 we presented a framework to Evaluate startups. The framework lays out several criteria along which you may evaluate startups. Market size is one of those criteria. Disclaimer: Propel(x) is a funding platform, not a Broker-Dealer. Securities are offered through Hubble Investments, member FINRA/SIPC and an affiliate of Propel(x). Private investments are highly illiquid and risky and are not suitable for all investors. Past performance is not indicative of future results. You should speak with your financial advisor, accountant, and/or attorney when evaluating private offerings. Neither Propel(x) nor Hubble Investments makes any recommendations or provides advice about investments. In this Episode, Andy and Swati discuss how to understand the Market for a startup. Questions we discuss are: Why is an understanding of market potential relevant (and what is market potential anyway)? How should one estimate the market size? Does every startup really have to have a humungous market running into many billions of dollars? Join us as we discuss these topics and more, that surround the key elements of startup evaluation - Market Size.

Join us as we interview our guest - Kiki Tidwell - a prolific angel investor, philanthropist, and cleantech evangelist. Among her many activities, Kiki is also a Founding Member of the Tech Advisory Group for the Stanford Center for Human Rights and International Justice. More on Kiki here: https://humanrights.stanford.edu/people/kiki-tidwell In this episode, we discuss how Kiki invests. Her process - starting from sourcing deal-flow, conducting diligence, evaluating the team and more. Kiki also shares her insights on success and failure and how to build a portfolio. We must emphasize, as always, that investing in early stage, unproven startups, is a high risk activity. There is no exact science to evaluating these companies. These investments carry the risk of complete capital loss. Disclaimer: Propel(x) is a funding platform, not a Broker-Dealer. Securities are offered through Hubble Investments, member FINRA/SIPC and an affiliate of Propel(x). Private investments are highly illiquid and risky and are not suitable for all investors. Past performance is not indicative of future results. You should speak with your financial advisor, accountant, and/or attorney when evaluating private offerings. Neither Propel(x) nor Hubble Investments makes any recommendations or provides advice about investments.